First Report Customer Care 
All time: 4.6

Latest / Last 30 Days: 5.0

527 Reviews

Credit Rating - KINIKSA PHARMACEUTICALS (UK), LTD.

ANALYSIS
Credit Risk Update: ACCOUNTS DUE FLAG: KINIKSA PHARMACEUTICALS (UK), LTD., KINIKSA PHARMACEUTICALS (UK) LTD, THIRD FLOOR, 23 OLD BOND STREET, LONDON, W1S 4PZ. The legal status is a Private Limited Company and the current status at the registry of companies is Active. The last filed accounts are dated 31 December 2022. The company was incorporated on 6 December 2018.

The accounts next due date is 30 September 2024. There are no mortgages.

The above was based on public record information as at 4 November 2024 and may not reflect the current status. Please access the current report to ascertain the current status and credit rating.
SUMMARY
Registered Number: 11716038
Date Incorporated: 6 December 2018
Date Latest Accounts: 31 December 2022
BUSINESS INFORMATION
Legal Form: Private Limited Company
Previous Names: None
Registered Number: 11716038
Annual Return: Unknown
Registered Office: KINIKSA PHARMACEUTICALS (UK) LTD, THIRD FLOOR, 23 OLD BOND STREET, LONDON, W1S 4PZ
SIC Code and Operations: 21100
SECURED CREDITORS
Number of Mortgages 0
Satisfied Mortgages 0
Part Satisfied Mortgages 0
Unsatisfied Mortgages 0
CREDIT RISK RATING
This is the credit risk assessment used by one of the top UK credit reference agencies.
Risk Score (1-100):

KINIKSA PHARMACEUTICALS (UK), LTD.

Click Here

to view this information

Risk Assessment:
Credit Rating:



First Report Score: (0-10):

Financial Status Guide:
10  trafficlight Very Strong
9   Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical
Report Created On 14 November 2024 Copyright © 2024 First Report Ltd


Recent Searches

Reg No. Reg Name Status
15630565 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC Active
11604916 KINILAW LIMITED Active - Proposal to Strike off
10928798 KINI-LDN LTD Dissolved
15708111 KINILI LTD Active
07346520 KINIMACHO LTD Active

In using this service you agree to the Terms and Conditions

© 2024 First Report Ltd